{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:36:31Z","timestamp":1790476591182,"version":"4.1.0"},"reference-count":116,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Respiratory Medicine"],"abstract":"<jats:p>Invasive pulmonary aspergillosis (IPA) presents a known risk to critically ill patients with SARS-CoV-2; quantifying the global burden of IPA in SARS-CoV-2 is extremely challenging. The true incidence of COVID-19-associated pulmonary aspergillosis (CAPA) and the impact on mortality is difficult to define because of indiscriminate clinical signs, low culture sensitivity and specificity and variability in clinical practice between centers. While positive cultures of upper airway samples are considered indicative for the diagnosis of probable CAPA, conventional microscopic examination and qualitative culture of respiratory tract samples have quite low sensitivity and specificity. Thus, the diagnosis should be confirmed with serum and BAL GM test or positive BAL culture to mitigate the risk of overdiagnosis and over-treatment. Bronchoscopy has a limited role in these patients and should only be considered when diagnosis confirmation would significantly change clinical management. Varying diagnostic performance, availability, and time-to-results turnaround time are important limitations of currently approved biomarkers and molecular assays for the diagnosis of IA. The use of CT scans for diagnostic purposes is controversial due to practical concerns and the complex character of lesions presented in SARS-CoV-2 patients. The key objective of management is to improve survival by avoiding misdiagnosis and by initiating early, targeted antifungal treatment. The main factors that should be considered upon selection of treatment options include the severity of the infection, concomitant renal or hepatic injury, possible drug interactions, requirement for therapeutic drug monitoring, and cost of therapy. The optimal duration of antifungal therapy for CAPA is still under debate.<\/jats:p>","DOI":"10.3390\/arm91030016","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T02:28:08Z","timestamp":1683599288000},"page":"185-202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape"],"prefix":"10.3390","volume":"91","author":[{"given":"Stavros","family":"Tsotsolis","sequence":"first","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, Leoforos Agiou Dimitriou, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-1341","authenticated-orcid":false,"given":"Serafeim-Chrysovalantis","family":"Kotoulas","sequence":"additional","affiliation":[{"name":"1st ICU, General Hospital of Thessaloniki \u201cGeorgios Papanikolaou\u201d, Leoforos Papanikolaou, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Lavrentieva","sequence":"additional","affiliation":[{"name":"1st ICU, General Hospital of Thessaloniki \u201cGeorgios Papanikolaou\u201d, Leoforos Papanikolaou, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: Importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e200430","DOI":"10.1590\/0074-02760200430","article-title":"Invasive fungal disease in humans: Are we aware of the real impact?","volume":"115","author":"Firacative","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_4","unstructured":"(2023, February 03). Gaffi\u2014Global Action Fund for Fungal Infections. Available online: https:\/\/www.gaffi.org."},{"key":"ref_5","unstructured":"(2023, February 03). Burden of Fungal Diseases in the United States. Fungal Diseases. CDC, Available online: https:\/\/www.cdc.gov\/fungal\/cdc-and-fungal\/burden.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of Direct Healthcare Costs of Fungal Diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001-2010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3109\/13693786.2012.755574","article-title":"Epidemiology of visceral mycoses in autopsy cases in Japan: The data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan","volume":"51","author":"Suzuki","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3109\/13693786.2010.505206","article-title":"Invasive aspergillosis in developing countries","volume":"49","author":"Chakrabarti","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1222236","article-title":"Tackling human fungal infections","volume":"336","author":"Brown","year":"2012","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","article-title":"Influenza-Associated Aspergillosis in Critically Ill Patients","volume":"196","author":"Kolwijck","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmi.2020.07.047","article-title":"Invasive aspergillosis in patients with severe COVID-19 pneumonia","volume":"27","author":"Helleberg","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2213-2600(20)30237-X","article-title":"Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19","volume":"8","author":"Alanio","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","article-title":"COVID-19-associated Pulmonary Aspergillosis","volume":"202","author":"Rijpstra","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/myc.13096","article-title":"COVID-19 associated pulmonary aspergillosis","volume":"63","author":"Koehler","year":"2020","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3201\/eid2607.201603","article-title":"Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient","volume":"26","author":"Blaize","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","article-title":"Clinical and virological data of the first cases of COVID-19 in Europe: A case series","volume":"20","author":"Lescure","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1093\/cid\/ciaa1298","article-title":"A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU","volume":"73","author":"White","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/myc.13213","article-title":"Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity","volume":"64","author":"Machado","year":"2021","journal-title":"Mycoses"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciz391","article-title":"Influenza Coinfection: Be(a)ware of Invasive Aspergillosis","volume":"70","author":"Verweij","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jfma.2017.06.002","article-title":"Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections","volume":"116","author":"Ku","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3201\/eid2704.204895","article-title":"COVID-19\u2013Associated Pulmonary Aspergillosis, March\u2013August 2020","volume":"27","author":"Sprute","year":"2021","journal-title":"Emerg. Infect. Di.s"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/infdis\/jiab163","article-title":"Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA)","volume":"26","author":"Lamoth","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lahmer, T., Kriescher, S., Herner, A., Rothe, K., Spinner, C.D., Schneider, J., Mayer, U., Neuenhahn, M., Hoffmann, D., and Geisler, F. (2021). Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0238825"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ofaa242","DOI":"10.1093\/ofid\/ofaa242","article-title":"Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19","volume":"7","author":"Cornely","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S2666-5247(20)30009-4","article-title":"Co-infections: Potentially lethal and unexplored in COVID-19","volume":"1","author":"Cox","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13613-020-00686-4","article-title":"COVID-19-associated invasive pulmonary aspergillosis","volume":"10","author":"Rutsaert","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2002554","DOI":"10.1183\/13993003.02554-2020","article-title":"Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis","volume":"56","author":"Youngs","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ii23","DOI":"10.1093\/jac\/dkw393","article-title":"The current management landscape: Aspergillosis","volume":"71","author":"Maertens","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MCP.0000000000000834","article-title":"Chronic obstructive pulmonary disease and COVID-19: Interrelationships","volume":"28","author":"Singh","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_38","first-page":"1775","article-title":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s00134-007-0791-z","article-title":"Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients","volume":"33","author":"Trof","year":"2007","journal-title":"Intensive Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis among Intubated Patients with COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","article-title":"Invasive pulmonary aspergillosis complicating severe influenza: Epidemiology, diagnosis and treatment","volume":"31","author":"Vanderbeke","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM200307313490519","article-title":"Fatal aspergillosis in a patient with SARS who was treated with corticosteroids","volume":"349","author":"Wang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J.A.C., Murthy, S., Diaz, J.V., Slutsky, A.S., Villar, J., Angus, D.C., Annane, D., Azevedo, L.C.P., and Berwanger, O. (2020). Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA, 324, 1330\u20131341.","DOI":"10.1001\/jama.2020.17023"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2021). Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1164\/rccm.201906-1185ST","article-title":"Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline","volume":"200","author":"Hage","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"3rd.; Denning, D.W.; Fishman, J.A.; Hadley, S.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Nguyen, M.H.; et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","first-page":"3721","article-title":"Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology","volume":"61","author":"Thornton","year":"2012","journal-title":"J. Vis. Exp."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(05)70238-3","article-title":"Laboratory diagnosis of invasive aspergillosis","volume":"5","author":"Hope","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0065-2164(10)70006-X","article-title":"Detection of invasive aspergillosis","volume":"70","author":"Thornton","year":"2010","journal-title":"Adv. Appl. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1128\/JCM.43.12.5957-5962.2005","article-title":"Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections","volume":"43","author":"Pickering","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2666-5247(20)30027-6","article-title":"Diagnosing COVID-19-associated pulmonary aspergillosis","volume":"1","author":"Verweij","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/CVI.00268-09","article-title":"Comparison of Lateral Flow Technology and Galactomannan and (1\u21923)-\u03b2-d-Glucan Assays for Detection of Invasive Pulmonary Aspergillosis","volume":"16","author":"Wiederhold","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12281-017-0275-8","article-title":"Lateral Flow Assays for the Diagnosis of Invasive Aspergillosis: Current Status","volume":"11","author":"Heldt","year":"2017","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/myc.12704","article-title":"Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis","volume":"61","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/LBR.0000000000000681","article-title":"American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients with Suspected or Confirmed COVID-19 Infection","volume":"27","author":"Wahidi","year":"2020","journal-title":"J. Bronchol. Interv. Pulmonol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11101-011-9216-2","article-title":"Volatile sesquiterpenes from fungi: What are they good for?","volume":"11","author":"Kramer","year":"2012","journal-title":"Phytochem. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-017-0183-9","article-title":"Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review","volume":"7","author":"Bassetti","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/ciu725","article-title":"A Breath Fungal Secondary Metabolite Signature to Diagnose Invasive Aspergillosis","volume":"59","author":"Koo","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/myc.12967","article-title":"Gliotoxin and bis(methylthio)gliotoxin are not reliable as biomarkers of invasive aspergillosis","volume":"62","author":"Mercier","year":"2019","journal-title":"Mycoses"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/JCM.00345-17","article-title":"Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis","volume":"55","author":"Zhou","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/512812","article-title":"Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens","volume":"44","author":"Rickerts","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1080\/13693780802227159","article-title":"Invasive aspergillosis in glucocorticoid-treated patients","volume":"47","author":"Lewis","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zou, M., Tang, L., Zhao, S., Zhao, Z., Chen, L., Chen, P., Huang, Z., Li, J., Chen, L., and Fan, X. (2012). Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043347"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1378\/chest.10-0488","article-title":"Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: A bivariate metaanalysis and systematic review","volume":"138","author":"Guo","year":"2010","journal-title":"Chest"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2015.05.017","article-title":"Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test","volume":"46","author":"Eigl","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","first-page":"CD012399","article-title":"Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients","volume":"5","author":"Gerritsen","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11046-012-9579-y","article-title":"Detection of (1, 3)-\u03b2-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts","volume":"175","author":"Theel","year":"2013","journal-title":"Mycopathologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/JCM.03233-15","article-title":"Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model","volume":"54","author":"White","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen Testing","volume":"61","author":"White","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/JCM.01365-14","article-title":"PCR in diagnosis of invasive aspergillosis: A meta-analysis of diagnostic performance","volume":"52","author":"Arvanitis","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis","volume":"61","author":"Arvanitis","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1473-3099(09)70019-2","article-title":"Use of PCR for diagnosis of invasive aspergillosis: Systematic review and meta-analysis","volume":"9","author":"Mengoli","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JCM.00467-14","article-title":"Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"52","author":"Hoenigl","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1099\/jmm.0.000092","article-title":"Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: A meta-analysis","volume":"64","author":"Pan","year":"2015","journal-title":"J. Med. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.201407-1275OC","article-title":"Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases","volume":"190","author":"Prattes","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"027108","DOI":"10.1088\/1752-7163\/aa98a1","article-title":"Breath-based diagnosis of fungal infections","volume":"12","author":"Acharige","year":"2018","journal-title":"J. Breath Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00253-015-7209-6","article-title":"Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis","volume":"100","author":"Domingo","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.riam.2016.05.007","article-title":"Disseminated aspergillosis in an immunocompetent patient with detectable bis(methylthio)gliotoxin and negative galactomannan","volume":"34","author":"Domingo","year":"2017","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1086\/518852","article-title":"Invasive aspergillosis in the intensive care unit","volume":"45","author":"Meersseman","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/jac\/dkw111","article-title":"Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection","volume":"71","author":"Barchiesi","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40121-020-00315-4","article-title":"Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment","volume":"9","author":"Russo","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2174\/156802662022200917110102","article-title":"Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options","volume":"20","author":"Silva","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Arastehfar, A., Carvalho, A., van de Veerdonk, F.L., Jenks, J.D., Koehler, P., Krause, R., Cornely, O.A., Perlin, D.S., Lass-Fl\u00f6rl, C., and Hoenigl, M. (2020). COVID-19 Associated Pulmonary Aspergillosis (CAPA)\u2014From Immunology to Treatment. J. Fungi, 6.","DOI":"10.3390\/jof6020091"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Baddley, J.W., Stephens, J.M., Ji, X., Gao, X., Schlamm, H.T., and Tarallo, M. (2013). Aspergillosis in Intensive Care Unit (ICU) patients: Epidemiology and economic outcomes. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-29"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1093\/jac\/dkx033","article-title":"New pharmacological opportunities for the treatment of invasive mould diseases","volume":"72","author":"Ledoux","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"ofaa105","DOI":"10.1093\/ofid\/ofaa105","article-title":"Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","article-title":"Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole","volume":"9","author":"Moriyama","year":"2015","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14787210.2016.1207526","article-title":"Pharmacodynamic studies of voriconazole: Informing the clinical management of invasive fungal infections","volume":"14","author":"Job","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Ther. Clin. Risk Mana.g"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: Current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and Renal Tropism of SARS-CoV-2","volume":"383","author":"Puelles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_105","first-page":"5186","article-title":"SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron microscopy","volume":"24","author":"Pesaresi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the Treatment of Invasive Aspergillosis: From Laboratory to Bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.366.6464.407","article-title":"New drugs target growing threat of fatal fungi","volume":"366","author":"Kupferschmidt","year":"2019","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Aldrees, A., Ghonem, L., Almajid, F., Barry, M., Mayet, A., and Almohaya, A.M. (2021). Evaluating the Inappropriate Prescribing and Utilization of Caspofungin, a Four-Year Analysis at a Teaching Hospital in Saudi Arabia. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121498"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Estella, \u00c1., Recuerda N\u00fa\u00f1ez, M., Lagares, C., Gracia Romero, M., Torres, E., Alados Arboledas, J.C., Ant\u00f3n Escors, \u00c1., Gonz\u00e1lez Garc\u00eda, C., Sandar N\u00fa\u00f1ez, D., and L\u00f3pez Prieto, D. (2023). Anticipatory Antifungal Treatment in Critically Ill Patients with SARS-CoV-2 Pneumonia. J. Fungi, 9.","DOI":"10.3390\/jof9030288"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Van Daele, R., Bekkers, B., Lindfors, M., Broman, L.M., Schauwvlieghe, A., Rijnders, B., Hunfeld, N.G.M., Juffermans, N.P., Taccone, F.S., and Sousa, C.A.C. (2021). A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation. Microorganisms, 9.","DOI":"10.3390\/microorganisms9071543"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Reizine, F., Pinceaux, K., Lederlin, M., Autier, B., Guegan, H., Gacouin, A., Luque-Paz, D., Boglione-Kerrien, C., Bacle, A., and Le Dar\u00e9, B. (2021). Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different?. J. Fungi, 7.","DOI":"10.21203\/rs.3.rs-331976\/v1"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"666296","DOI":"10.3389\/fphar.2021.666296","article-title":"Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole","volume":"12","author":"Jia","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"Pickkers","year":"2022","journal-title":"Nat. Med."}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/91\/3\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:31:31Z","timestamp":1760124691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/91\/3\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":116,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["arm91030016"],"URL":"https:\/\/doi.org\/10.3390\/arm91030016","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]}}}